SCHEMBL4538568

SCHEMBL4538568

NCc1cc(S(=O)(=O)c2cccc(C(F)(F)F)c2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.49
AKR1B1 P15121 1/20 0.46
HSP90AA1 P07900 1/20 0.45
CXCR5 P32302 1/20 0.45
APLNR P35414 1/20 0.45
CCR6 P51684 1/20 0.45
CA2 P00918 2/20 0.44
CA1 P00915 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44
NOTUM Q6P988 1/20 0.44
NAMPT P43490 9/20 0.43
SLC40A1 Q9NP59 1/20 0.43
TSHR P16473 1/20 0.42
CLK1 P49759 1/20 0.42
PIK3CA P42336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4542082 0.83 NAMPT (0.54) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL7138728 0.81 HTR6 (0.49) HTR6NAMPT
SCHEMBL7142058 0.81 AKR1B1 (0.43) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL15530366 0.80 NAMPT (0.53) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL27457358 0.79 AKR1B1 (0.49) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL30859041 0.79 CA1 (0.65) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL8863056 0.79 CA1 (0.65) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL4538358 0.79 HTR6 (0.50) HTR6AKR1B1HSP90AA1CXCR5APLNR
SCHEMBL4537377 0.79 NAMPT (0.50) HTR6AKR1B1HSP90AA1CXCR5APLNR
Hydrochloric Acid SCHEMBL11261755 0.77 CA1 (0.62) HTR6AKR1B1HSP90AA1CXCR5APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 US disclosed
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 US disclosed
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 US disclosed
WO-2012061926-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1S, KCNN4 HTR6 1199/4885AKR1B1 685/4885HSP90AA1 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.